Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion    OXUR   BE0003846632

OXURION

(OXUR)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
4.175(c) 4.2(c) 4.235(c) 4.11(c) 4.02(c) Last
33 824 37 039 21 875 109 832 43 589 Volume
+0.24% +0.60% +0.83% -2.95% -2.19% Change
More quotes
Financials (EUR)
Sales 2018 5,50 M
EBIT 2018 -30,5 M
Net income 2018 -29,0 M
Finance 2018 56,0 M
Yield 2018 -
Sales 2019 6,00 M
EBIT 2019 -30,0 M
Net income 2019 -28,0 M
Debt 2019 4,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 17,8x
EV / Sales2019 26,3x
Capitalization 154 M
More Financials
Company
Oxurion (formerly ThromboGenics) specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (86.1%); - royalties (13.9%). 
More about the company
Surperformance© ratings of Oxurion
Trading Rating : - Investor Rating :
More Ratings
Latest news on OXURION
2018OXURION : licences heparanase blockers from Beta Therapeutics
AQ
2018OXURION : and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatme..
PU
2018OXURION : November is Diabetic Eye Disease Awareness Month at Prevent Blindness
PU
2018OXURION : Announces the Appointment of Adrienne Graves to its Board of Directors
PU
2018OXURION : to Present at the Upcoming Ophthalmology Innovation Summit and Provide..
AQ
2018OXURION : to Present at the Upcoming Ophthalmology Innovation Summit and Provide..
PU
2018OXURION : Extends Partnership with Retina Global in Support of Bolivian Diabetic..
PU
2018OXURION : Business Update – Q3 2018
PU
2018OXURION : NV Business Update - Q3 2018
GL
2018OXURION : 3rd quarter results
CO
More news
Analyst Recommendations on OXURION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OXURION
Duration : Period :
Oxurion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,75 €
Spread / Average Target 43%
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
OXURION11.05%174
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477